N NATCO PHARMA USA
Live / Allowed — Published for opposition (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 04 Sept 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99375173
- Mark type
- Design + words
- Filed
- 04 Sept 2025
- Published for opposition
- 10 Mar 2026
- Attorney of record
- Michael A. Marrero
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of gastroparesis, labyrinthitis, and angina
- Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals
- Class 042 — Scientific and technological services: Research and development services in the field of pharmaceutical preparations; Pharmaceutical drug development services; Development of pharmaceutical preparations and medicines; Pharmaceutical research and development
Owner
- Natco Pharma USA LLC, Parsippany, NJ, US
- Natco Pharma USA LLC, Parsippany, NJ, US
Prior registrations
Prosecution history
- 10 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Mar 2026 — PUBLISHED FOR OPPOSITION
- 04 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Feb 2026 — EXAMINER'S AMENDMENT ENTERED
- 18 Feb 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 18 Feb 2026 — EXAMINERS AMENDMENT E-MAILED
- 18 Feb 2026 — EXAMINERS AMENDMENT -WRITTEN
- 17 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Feb 2026 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 14 Feb 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 14 Feb 2026 — FINAL REFUSAL E-MAILED
- 14 Feb 2026 — FINAL REFUSAL WRITTEN
- 29 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED